RecruitingNCT06331208

Mechanisms of Pulmonary Vascular Dysfunction in Heart Failure


Sponsor

Institute for Clinical and Experimental Medicine

Enrollment

230 participants

Start Date

Aug 23, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

Heart failure (HF) patients often develop pulmonary hypertension (PH) that leads to transition into a biventricular HF with poor prognosis. There are two PH components: 1) passive transmission of increased left atrial pressure, 2) heart failure (HF) related pulmonary vascular dysfunction (PVD) with increased vascular resistance. Intriguingly, only some, but not all HF patients develop heart failure-related PVD. The mechanisms and non-invasive detection of HF-PVD are poorly understood and are the focus of the current grant application. Development of PVD is linked to insufficiently characterized metabolic factors that may be mediators of HF-PVD. Untargeted metabolomics is an emerging powerful platform for the discovery of pathways linked to diseases. Its specificity can be further enhanced using transpulmonary gradient sampling. Part A of the project aims to identify novel metabolites associated with the presence of PVD in patients with HF that can serve as biomarkers or targets and will provide biologic insights into PVD. Part C will assess the effects of reverting of metabolic alterations (identified in part A) by a drug/diet on pulmonary vasculature in experimental HF-related PVD. The "gold standard" for the detection of PVD is right heart catheterization, which is invasive and risky. Heart failure-related PVD is therefore often diagnosed late. There is a need for noninvasive tests that may help to detect PVD in early stages and can be done repeatedly. Recent advances in artificial intelligence (AI)-assisted automated quantitative analysis of lung texture from low-dose contrast-free high-resolution CT images allow to quantify lung water content, interstitial changes or vessel volume, and may provide clues for detection of heart failure-related PVD. Such an approach, not tested yet, will be utilized for the detection of HF-PVD (part B). Clinical and functional characteristics of lung circulation (exercise hemodynamics, diffusion capacity, perfusion) will be analyzed in relation to quantitative CT data.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating what happens to the blood vessels in the lungs in people with heart failure — a condition where the heart can't pump blood efficiently. Over time, heart failure can damage the blood vessels in the lungs (pulmonary vasculature), making the condition worse. Researchers will study patients undergoing a procedure called right heart catheterization (a tube placed in the heart to measure pressures) to better understand these changes and potentially identify new treatment targets. **You may be eligible if (Heart Failure group):** - You are over 18 years old - You have been diagnosed with heart failure for at least 6 months with reduced pumping function (ejection fraction below 50%) - You are on water pills (loop diuretics) and have a medical reason to undergo right heart catheterization **You may be eligible if (Control group):** - You are over 18 years old - You do not have heart failure and are coming in for another scheduled procedure (such as closure of a heart hole or arrhythmia ablation) **You may NOT be eligible if:** - You are hemodynamically unstable and need medications to support your blood pressure - You have severe kidney problems, an acute heart attack, or severe lung disease - You have a type of pulmonary hypertension not caused by heart failure Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTnon-contrast chest CT

patients who undergo clinically indicated evaluation of pulmonary circulation (right heart catheterisation - RHC) will undergo non-contrast CT of the chest, blood sampling from pulmonary artery and spirometry with DLCO analysis.

DIAGNOSTIC_TESTspirometry with diffusing lung capacity for carbon monoxide (DLCO) analysis

patients who undergo clinically indicated evaluation of pulmonary circulation (RHC) will undergo non-contrast CT of the chest, blood sampling from pulmonary artery and spirometry with DLCO analysis.

DIAGNOSTIC_TESTOmics analysis of blood plasma obtained from pulmonary artery or peripheral blood

patients who undergo clinically indicated evaluation of pulmonary circulation (RHC) will undergo non-contrast CT of the chest, blood sampling from pulmonary artery and spirometry with DLCO analysis.

DIAGNOSTIC_TESTsupine bike exercise during right heart catheterisation

subgroup of HF subjects who undergo right heart catheterisation will perform short supine bike exercise during RHC

DIAGNOSTIC_TESTLung ventilation/perfusion SPECT

subgroup of HF subjects will undergo ventilation/perfusion SPECT


Locations(1)

Institute for Clinical and Experimental Medicine - IKEM

Prague, Czechia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06331208


Related Trials